Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Drugs in Trials
Printable versionPrintable version
Drug Development status Clinical Trial ID Company or Institution Mechanism Notes
A437203 Preclinical   Abbott D3 antagonist  
ABT925 POC Failed NCT00412620 Abbott D3-R antagonist Insufficient target engagement
AF11167 Phase 1   Lundbeck PDE inhibitor Also aimed at AD and HD
AMG579 Phase 2   Reviva PDE10 inhibitor  
Asenapine (Org5222) FDA Approved NCT00156104 Merck-Schering 5HT2-D2 antagonist  
AT-9242 Phase 1   ARYx Engineered antipsychotic clozapine-analog Origin Schwartz
AZ-004 (ALXZ-004) Phase 3   Alexza Pharmaceuticals Inhaled loxapine  
Bifeprunox Discontinued NCT00366327 Solvay 5HT2A & D2 partial agonist Development halted
BL-1020 Phase 3 Failed   Bio-LineRx DA antagonist with GABA modulation  
Blonanserine (AD5423) Phase 3   Dainippon DA-5HT2 antagonist  
Cariprazine (RGH188) Phase 3   Richter Pharma AG D2/D3 modulator Complete Response Letter by FDA
CLR151 Inactive   Clera Inc. Fast off D2R antagonist  
DAAOI-1 POC Ongoing NCT01390376 China Medical University Hospital Regulates D-serine levels Treatment-resistant schizophrenia patients stand-alone
DAR0100-Dihyrexidine (N-(N-Propyl)-Dihydrexidine) Phase 2   Purdue Pharma Partial D1 agonist; restores frontal dopaminergic deficit Add-on for negative symptoms, improves cognition
DAR-100 POC Failed     Full D1R agonist Matrics scale did not show improvement when added to D1R-sparing antipsychotics; 15 mg <1% target engagement
DAR201 Inactive   DAR Pharma D1 agonist No development reported
Dinapsolin Inactive   BioValve D1 agonist  
EGIS-11150 Preclinical   Egis Pharma D2R antagonist with effect on adrenergic and serotonergic receptors  
Eltoprazine POC Ongoing NCT01266174 Psychogenics 5-HT modulator Cognitive impairment augmentation therapy
Entacapone Inactive NCT00192855 Ramban Health Center COMT inhibitor Add-on for cognitive disorders
F15063 Discontinued   Fabre D2-D3 antagonist, D4 5HT1A agonist  
F17464 Phase 2 NCT02151656 Pierre Fabre Selective D3 antagonist/5-HT1A partial agonist Imaging study in healthy volunteers
F17807 Preclinical   Pierre Fabre D3/D2/alpha2C antagonist Treatment-resistant schizophrenia, CIAS
GSK773812 (G773812, SB-773812) Inactive NCT00259870 GlaxoSmithKline D2 5HT2 antagonist  
Iloperidone FDA Approved NCT00254202 Vanda DA-5HT2 antagonist Originally developed by Novartis
ITI-007 POC Successful NCT01499563 Intra-Cellular Therapeutics D2, 5HT2A antagonist, SERT block + dopamine phosphoprotein modulator inlicensed from BMS; successful Phase 2 trial compared to Risperdal, shows target engagement at 10 mg using PET
JNJ37822681 Inactive   Janssen Fast off D2R antagonist  
L-Dopa POC Ongoing NCT01636037 Center for Addiction & Mental Health Dopamine stabilization Augmentation therapy for negative/cognitive symptoms
Loxapine FDA Approved   Alexza Pharmaceuticals DA-5HT2A antagonist Addresses agitation, uses inhalation technology
Lu 31-130 Phase 2   Lundbeck DA-5HT2 antagonist  
Lurasidone (SM13496) FDA Approved   Dainippon D2 antagonist 5HT2A antagonist  
Modafinil POC Failed NCT00057707, NCT00573417 National Institute of Mental Health (NIMH) DA outflow enhancer Add-on trial failed
MP-10 Phase 2 NC1939548 Pfizer PDE10 inhibitor Augmentation therapy
NPD-001 Preclinical   Omeros Phosphodiesterase 10 inhibitor  
Ocaperidone Discontinued   Neuro3D D2 5HT2 antagonist Inlicensed from Janssen; development halted
OMS643762 POC Ongoing NCT01952132 Omeros PDE-10 inhibitor Cognition both stand-alone and as augmentation therapy
OPC-34712 (Brexpiprazole) Phase 2 NCT01451164 Otsuka Pharmaceutical Co., Ltd. Partial D2 agonist Dose-finding study
Paliperidone palmitate (9-hydroxyrisperidone) FDA Approved NCT00210548 Janssen DA-5HT2 antagonist (serotonin-dopamine antagonist, or SDA)  
PF-2545920 POC Failed NCT00463372 Pfizer PDE10 Collaboration with Biotie-elbion
PGX200097 Discontinued   Psychiatry Genomics D2R antagonist COMT inh  
Pimozide POC Failed NCT00158223 National Institute of Mental Health (NIMH) Antipsychotic No effect
PNU177864 Inactive   Pfizer D3 antagonist Severe skeletal myopathy in rodents
Pramipexol Inactive   St. Vincent’s Hospital Westchester, Hanover, NJ D3 agonist Add-on to risperidone
Preclamol ((-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine [(-)-3PPP) Inactive   University of Maryland D2 agonist; Partial D1 R agonist Cognitive enhancement
Pyrimidine-Ones Discontinued   Ferrer DA-5HT2 antagonist  
QF2004B Discontinued   Santiago de Compostela 5HT2A D2 antagonist  
RP5063 Phase 2 NCT01490086 Reviva DA-5HT stabilizer Substantial effect of 23 points on PANSS Total vs. 15 for aripiprazole
SB269235 Inactive   GlaxoSmithKline D3 antagonist  
SB-773812 Discontinued NCT00259870 GlaxoSmithKline D2, 5HT2A, 5HT6, D3 antagonist Target engagement data
SLV-314 Inactive   Solvay D2 antagonist SSRI  
SLV319 Inactive   Solvay D2 antagonist 5HT1A agonist CB1-R antagonist Also in development for obesity
ST2329 Discontinued   Sigma-Tau 5Ht2A-D3 antagonist  
Stepholidine POC Ongoing   University of Toronto D2 antagonist-D1 agonist Derived from Chinese herbs
Tolcapone Inactive NCT00044083 National Institute of Mental Health (NIMH) COMT inhibitor Add-on for cognitive disorders
Unknown: BMS Discovery     PDE10; Modulates dopamine dynamics on direct vs indirect pathway specifically in striatum  
Unknown: Janssen Phase 1   Janssen PDE10 inhibitor Collaboration with Biotie-Elbion
Unknown: Lundbeck Discovery   Lundbeck PDE10; Modulates dopamine dynamics on direct vs indirect pathway specifically in striatum  
Unknown: Roche Discovery   Roche PDE10; Modulates dopamine dynamics on direct vs indirect pathway specifically in striatum  
YKP1358 Phase 2   SK Bio-Pharmaceuticals D2, D3 5HT-2A antagonist, no action at adrenerge receptors PET imaging data available
Printable versionPrintable version
Drug Development status Clinical Trial ID Company or Institution Mechanism Notes
AA21279 Preclinical   Lundbeck GlyT1 inhibitor  
ADX71149 Phase 2   Addex mGluR2 PAM  
AMG747 Phase 2 NCT01568229 Reviva GlyT1 inhibitor  
AZD9272 Phase 1   AstraZeneca mGLUR1 antagonist  
BFF-816 Preclinical   Mitsubishi KATII antagonist  
CX516 Discontinued NCT00235352 Cortex Positive modulator of AMPA subtype of glutamate receptor No effect on cognition as add-on
D-serine Discontinued NCT00138775 Glytech NMDA enhancer; add-on No different from placebo
Glycine Inactive NCT00291226 Glytech Direct agonist of the gly site on NMDA-R Monotherapy; no different from placebo
GlyT1 inh Preclinical   Eli Lilly GlyT1 inhibitor Addresses cognitive/negative symptoms
GLYX-13 Preclinical   Naurex Gly site functional partial agonist; monoclonal antibody derived peptide Add-on to address cognitive/negative symptoms
GSK1018921 Discontinued NCT00929370 GlaxoSmithKline GlyT1 inhibitor Addresses cognitive/negative symptoms
GSK729327 Discontinued NCT00448890 GlaxoSmithKline AMPA modulator Also in development for dementia
JNJ17305600 Discontinued   Allelix GlyT1 inhibitor  
LY404039 Preclinical   Eli Lilly mGluR2/R3 agonist  
Memantine POC Completed NCT00757978 Rio Grande, Brazil NMDA antagonist Add-on to clozapine shows improvement in negative symptoms
Memantine + Donepezil Inactive   University of California, Irvine NMDA antagonist, AChE inhibitor  
mGluR8A Discontinued   NPS Pharma mGLuR8 positive modulator  
MGS0039 Preclinical   Merck mGluRII modulators Addresses depressive symptoms in schizophrenia
Neboglamine (XY-240) Inactive   Rottapharm Gly site pos modulator Cognitive enhancer add-on
NPSP156 Discontinued   NPS Pharma D-serine analog Add-on for cognitive deficits
ORG24448 (CX691) Discontinued NCT00425815 Merck   Cognitive enhancer add-on supported by MATRICS, no results reported
Org25925 POC Failed   Merck GlyT1 antagonist No clinical effect
ORG25935 Phase 1   Merck GlyT1 inhibitor Reverts ketamine induced psychotic effects
PF-04802540 (TS-032) Phase 2 NCT00876304 Pfizer mGluR2 agonist Effect on sleep
PF3311945 Phase 2   Pfizer GlyT1 inhibitor  
Pomaglumetad Methionil Discontinued NCT01487083 Eli Lilly mGluR2/3 agonist Failed in Phase 3 trials as stand-alone
R1678 (Bitopertin) Phase 3 Failed NCT00616798 Roche GlyT1 inhibitor Pos Phase 2 data in negative and cognitive symptoms
Riluzole Inactive NCT00375050 Yale University NMDA antagonist Add-on for cognitive disorders
Sarcosine Phase 2 NCT00276263 Herzog Hospital, Israel NMDA enhancer; add-on Showed modest efficacy in Phase 2 trial (effect size between 0.35 and 0.40 for non-clozapine augmentation); no effect for clozapine augmentation
Unknown: Merck Discovery   Merck mGluR5 inhibitor Collaboration with Addex Pharmaceuticals
Unknown: Promentis Preclinical   Promentis Pharmaceuticals Cysteine-Glu antiporter blocker  
WAY212922 Preclinical   Wyeth EAAT2 inhibitor  
Printable versionPrintable version
Drug Development status Clinical Trial ID Company or Institution Mechanism Notes
ABBF (EVP6124) POC Successful   EnVivo Pharmaceuticals α7 nAChR agonist Add-on for cognitive deficit; licensed in from Bayer
ABT089 Phase 2 NCT00391729 Abbott nAChR agonist Cognitive enhancer add-on; now in development only for ADHD
ABT-107 Discontinued   Abbott Nicotinic receptor modulator Halted March 2009
ABT-126 POC Ongoing   Abbott Nicotinic receptor modulator Positive data reported for AD
AQW051 Phase 2 NCT01730768 Novartis Pharmaceuticals a7 nAchR modulator Once daily doses for cognitive enhancement
AZ-123 Discontinued   AstraZeneca M4 positive allosteric modulator  
CD0304 Inactive   Cognitive Pharma M2 antagonist  
EVP-6124 (ABBF) Phase 3 NCT01716975 EnVivo Pharmaceuticals a7 nAChR agonist Licensed in from Bayer
Galantamine POC Failed NCT00176423 University of Maryland AChE-inhibitor, nAChR modulator Add-on for cognitive deficiency shows very moderate effects on negative symptoms but not on cognition
GTS-21 (DMXB-A) University of Florida Phase 3   University of Florida nAChR agonist Proof-of-concept study successful
GTS-21 (DMXB-A) Veterans Administration POC Completed NCT00100165 Veterans Administration Partial a7 nAChR agonist Cognitive add-on
Ispronicline (TC1374) Discontinued   AstraZeneca nAChR agonist Cognitive enhancer add-on; negative outcome
JNJ-39393406 Discontinued NCT01137799 Janssen α7 nACHR Positive allosteric modulator  
Mecamylamine POC Failed NCT00455650 Massachusetts General Hospital nAChR antagonist Prompts more smoking in schizophrenia
MEM3454 POC Failed   Memory Pharma α7 nACHR agonist Cognitive enhancer add-on als in development for Alzheimer's; Phase 2 trial in Matrics ineffective (ACNP 2009)
PNU-282987 Discontinued   Pfizer α7 nAChR Cardiac side effects in Phase 1
Sabcomeline (SB-202026) Inactive   Minster Research M1 agonist Previously used in Alzheimer's disease
SEN-WAY-X Discontinued   Sienabiotech α7 nAChR  
SSR180711 Discontinued   Sanofi α7 nAChR agonist  
TC2216 Discontinued NCT00583544 Targacept a4b2 nAChR inhibitor Might play a role in reversing depressive and negative symptoms
Transdermal Nicotine POC Completed   Harvard Medical Center Stimulates nACHR Cognitive enhancer add-on; enhances novelty detection
Unknown: Pfizer Discontinued   Pfizer a6 nAChR modulator Addresses cognitive/negative symptoms
Varenicline POC Completed NCT00455650 Massachusetts General Hospital Partial nAChR agonist Shows benefit to some cognitive outcomes as add-on, no effect on positive or psychopathology symptoms, reduces smoking partially
VRTX3 Discontinued   Vertex M1 M4 agonist Addresses glutamate dysfunction
Xanomeline POC Successful   Eli Lilly M1 agonist Previously used in Alzheimer's disease
Printable versionPrintable version
Drug Development status Clinical Trial ID Company or Institution Mechanism Notes
Adidiplon Discontinued   Neurogen GABA a3 partial agonist Development in insomnia
L-830982 POC Completed   University of Pittsburgh GABA α2/3 agonist Add-on for cognitive disorders; in development for general anxiety disorders
PW4123 Inactive   PennWest CNS modulator Also in development for epilepsy, formulation approach
Tiagabine POC Ongoing NCT00179465 Beth Israel Deaconess Medical Center GABA enhancer Add-on
Valproate Inactive   Beijing Anding Hospital, Capital University of Medical Sciences Ion-channel modulator Add-on therapy; no effect on stable and partial responsive schizophrenia patients
Printable versionPrintable version
Drug Development status Clinical Trial ID Company or Institution Mechanism Notes
ABT-288 Phase 1   Abbott H3 antagonist Also in development for Alzheimer's disease
BF2.649 Phase 2   University of Texas Southwestern H3 antagonist/inverse agonist Add-on for cognitive disorders, shows effect in narcolepsy
Ciproxifan Preclinical   INSERM H3 antagonist  
GSK189254 Discontinued NCT00387413 GlaxoSmithKline H3 antagonist First indication for narcolepsy; possibly addresses cognitive deficit in schizophrenia
MK0249 Phase 2 NCT00506077 Merck H3-antagonist Add-on for cognition; modest effect in Alzheimer's disease
Printable versionPrintable version
Drug Development status Clinical Trial ID Company or Institution Mechanism Notes
ACP103 (Pimavanserin) Discontinued NCT00361166 Acadia Pharma Inverse 5HT2A agonist Add-on therapy to reduce motor side effects
AE58054 POC Failed NCT00810667 Lundbeck 5HT6 antagonist Also developed in Alzheimer's disease
AR11-6081 Preclinical   Arena Inverse 5HT2A agonist No update since 2006
AV965 Preclinical NCT00156104 Avera Pharma 5HT1A partial agonist Acquired from Novartis
A-XXX Preclinical   Abbott 5HT5A antagonists  
B35490 Preclinical   BioFocus 5HT2A antagonist  
Eplivanserin Discontinued   Sanofi 5HT2A antagonist  
Escitalopram Discontinued NCT00148447 University of Pittsburgh 5HT transporter inhibitor Improves social and mental health and quality of life
LY482518 Phase 1   Eli Lilly 5HT6 antagonist Add-on for cognitive disorder
Naratriptan POC Ongoing NCT00282165 University of Utrecht, The Netherlands 5HT1D antagonist Add-on for aggressive outburts in convicts
Ondansetron POC Completed NCT00149734 National Institute of Mental Health (NIMH) 5-HT3 antagonist Shows improvement in PANSS total with haldol
PRX 07034 Discontinued   Epix 5HT6 antagonist  
SB 742457 Discontinued   GlaxoSmithKline 5HT6 antagonist Development in schizophrenia discontinued, further development in Alzheimer's disease; Improves memory consolidation
SCA719 Discontinued   Pfizer 5HT2C agonist  
SGS518 Inactive   Eli Lilly 5HT6 antagonist Cognitive enhancer add-on
Tropisetron POC Successful NCT00435370 National Institute of Mental Health (NIMH) 5-HT3 antagonist, and a7 nAChR modulator Shows improvement in cognitive tests as augmentation therapy
Printable versionPrintable version
Drug Development status Clinical Trial ID Company or Institution Mechanism Notes
ABS13 Discontinued   Argolyn Unspecified GPCR modulator No development since 2003
Acamprosate POC Ongoing NCT00463346 Forest Laboratories Reduces alcohol dependence in dual diagnosis  
AL-108 POC Failed   Allon Therapeutics Microtubule stabilizer Intranasal forumulation, add-on for cognition, failed POC in Matrics
ALKS 3831 POC Ongoing NCT01903837 Alkermes Olanzapine + ALKS33 opioid modulator Stand-alone
Amylin Hormone Preclinical   Amylin Hormone therapy  
Arthemeter Inactive   Wuhan University China Antibiotic Repurposed anti malaria and toxoplasmo add-on
aTMS POC Ongoing NCT01941251 Niuvanniemi Hospital Transcranial magnetic stimulation Treatment-resistant schizophrenia patients stand-alone
Atomoxetine POC Failed NCT00216281 University of Indiana NE/5HT transporter inhibitor No effect on cognition or negative symptoms as add-on; slight improvement of extra-pyramidal symptoms
AUT6 Preclinical   Autifony Therapeutics Kv3 K+ channel modulator  
AV1625 Inactive NCT00345410 Sanofi CB1-R antagonist In development for multiple indications
AZD2624 POC Failed NCT00686998 AstraZeneca NK3 antagonist No effect seen on cognitive and negative symptoms in schizophrenia
Bexarotene Phase 2   Ben-Gurion University of the Negev, Beersheba, Israel Retinoid X receptor antagonist Small open-label Phase 2 study positive
Cannabidiol Phase 2 NCT00309413 University of Cologne, Germany Endocannabinoid Monotherapy; fails to correct D9-THC induced P300 deficits in healthy volunteers
Celecoxib POC Completed   Beijing Hui-Long-Guan Hospital COX inhibitor Add-on to risperidone, small effect in Phase 2 study
Chelerythrine Preclinical   Marinus Pharma PKC inhibitor Improves PFC working memory; Repositioning (drug used as an ingredient in a marketed prescription based toothpaste and dental rinse)
CM2393 Inactive   Cenomed Unknown MoA  
CP96345 Preclinical   Pfizer NK1 antagonist  
CRD-101 Phase 1   Curidium Unknown MoA Repositioning of unknown existing drug
Creatine Phase 2 NCT00140192 Beersheva Mental Health Center Energy enhancer Add-on for correction of metabolic disorders
Curcumin POC Completed NCT00099710 University of Western Ontario Anti-inflammation Reduces oro-facial dyskinesia associated with neuroleptics
Dipyridamole Inactive NCT00349973 University of Maryland Adenosine agonist Stand-alone
Divalproex Sodium Phase 4 NCT00306475 Vanderbilt Na channel modulator Add-on therapy; no effect on stable and partial responsive schizophrenia patients
Duloxetine POC Completed NCT00224302 Mental Health, Mannheim, Germany 5-HT and NE transporter inhibitor Positive effect as add-on in depressive episodes, negative and general psychopathology with stable positive symptoms effect. No effect when added to clozapine.
Epigallocatechin Gallate Inactive   Portland VA Inhibition of NO Green tea polyphenol; add-on
EPO POC Completed   Max Planck Institute Neuroprotectant Small but significant effect as cognitive enhancer add-on in small Phase 2 study
Estradiol Phase 2 NCT00206570 University of Santander Hormonal substitution Augmentation therapy improves positive symptoms and psychopathology in women
Folate, B12, Pyridoxine: University of Melbourne Inactive   University of Melbourne, Victoria, Australia Antioxidant Neuroprotective add-on
Folate, VitB12, Pyridoxine: Nathan Kline Institute Inactive NCT00403247 Nathan Kline Institute Vitamin Add-on
GSK644784 Discontinued   GlaxoSmithKline COX2 inhibitor Dual acting COX inhibitor
Idazoxan Inactive   Potomac Pharma Alpha2 AR Withdrawn in treatment-resistant depression (Sheba Med Center)
Lamotrigine: University of Manchester POC Completed   University of Manchester Na-channel blocker; anticonvulsant  
Lamotrigine: XTL Phase 2   Amgen Na-channel blocker; anticonvulsant  
LAX101 (Miraxion; Ethyl-Eicosapentoic Acid) Inactive   Amarin Phospholipase inhibitor Also in development for Huntington's disease
L-carnosine Inactive   Pittsburgh Western Psychiatric Institute and Clinic Antioxidant and anti-glycosylation Cognitive enhancer
Low-Dose Lithium POC Completed NCT00202306 Melbourne Health, Australia GSK3 inhibitor Addresses clozapine-induced neutropenia in children
L-Theanine (Gamma-Glutamylethylamide) Inactive NCT00372151 Sha’ar Menashe Mental Health Center   Add-on for cognitive disorders, moduilates alpha EEG band
LX6171 Discontinued   Lexicon Inhibitor of SLC6A7, a high-affinity L-proline transporter part of GABA-Transporter family Cognitive enhancer add-on; failed in age-associated memory impairment; modulates balance between excitation & inhibition
LY500307 POC Ongoing NCT01874756 Indiana University Selective estrogen beta receptor Cognitive impairment augmentation therapy
MEM1003 (BAY-Z-4406) Inactive NCT00374920 Memory L-type Ca channel blocker Add-on for cognitive disorder; brain penetrant Nimodipine analog also in development for AD
Mifepristone (RU-486) Phase 3   Corlux Glucocorticoid -R antagonist No effect on neurocognition as add-on; further development in bipolar disorder
MK0557 Discontinued NCT00482430 Merck NPY antagonist Originally developed for obesitas
Neuregulin 1 Preclinical   Decode Neuregulin1 modulator  
Neurotensin Peptides Preclinical   Pfizer Neurotensin analogues  
NT69L Preclinical   Roche Neurotensin analogue  
NW3509 Preclinical   Newron Na-channel modulator  
Org 34517 Discontinued NCT00226278 Merck-Schering Selective glucocorticoid receptor antagonist Add-on for depressive symptoms
ORM-12741 Phase 1 NCT01068028 Orion Corporation Alpha2C antagonist Now in development for AD
Oxytocin POC Ongoing NCT01712646 National Institute of Mental Health (NIMH) Affects social behavior Daily intranasal oxytocin for childhood-onset schizophrenia
PF00184562 Inactive NCT00150215 Pfizer Unknown MoA  
Pioglitazone POC Ongoing   NYU School of Medicine and Manhattan Psychiatric Center PPAR-γ agonist Add-on to clozapine and olanzapine, treatment of antipsychotic induced hyperglycemia
Pravastatin POC Ongoing NCT00177580 University of Pittsburgh Cholesterol-lowering Add-on
Pregnelonone Inactive NCT00174889 Sha’ar Menashe Mental Health Center Neurosteroid, affecting GABA  
Raloxifene, Estradiol 2 mg plus Dyhydroprogesterone Phase 3 NCT01573637 Alfred Hospital Estrogen receptor modulator Augmentation therapy for negative symptoms
Reboxetine POC Completed NCT00409201 Arbabanel Mental Health Center Norepineprhine transport inhibitor One positive and one negative study; also beneficial effect on weight gain
RG1068 Discontinued   Repligen Secretin Addresses cognitive dysfunction
Rimonabant Inactive   Sanofi CB1-R antagonist Already approved for weight loss; tested in smoking cessation
Simvastatin Inactive   Columbia University, New York Add-on therapy, limited by drug-drug interactions and induction of rhabdyomelitis Add-on therapy, limited by drug-drug interactions and induction of rhabdyomelitis
Talnetant Discontinued NCT00049946 GlaxoSmithKline NK3 antagonist Completed
Taurine Inactive   University of Melbourne, Victoria, Australia Essential amino acid Add-on
Tetrabenazine POC Completed NCT00362804 University of Toronto Monoamine depleting agents Add-on to olanzapine reduces dystonia
Transcranial Direct Current Stimulation Phase 2 NCT00481026 Bayside Health Directly modifies brain signal processing  
Trimethropin POC Failed   University of Eritrea, Ethiopia Antibiotic Repurposed anti-bacterial add-on; no effect in Phase 2 study
Valacyclovir POC Failed NCT00175513 University of British Columbia Antiviral Adjunctive therapy in cytomegalovirs + patients shows no effect
W3 Fatty Acids Inactive NCT00167310 University of Pittsburgh Cardiac protection Add-on
WAY-XXX Discontinued   Pfizer Oxytocin receptor antagonist  

Copyright © 2005- 2016 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright